Lantheus Holdings, Inc. LNTH
At closeNov 4, 2026, 8:42 AM EST
Pre-market · Nov 4, 8:42 AM ET
- YTD
- +51.47%
- 1 year
- +77.40%
- Market cap
- 6.58B
- Revenue (ttm)
- 1.56B
- Profit margin
- 17.69%
- EPS (ttm)
- 4.13
- Shares out
- 65.30M
- P/E ratio
- 24.41
- Forward P/E
- 15.55
- YTD return
- +51.47%
- 1-year return
- +77.40%
- Volume
- 748.57K
- Avg volume
- 1.19M
- Open
- 100.26
- Previous close
- 100.31
- Day's range
- 100.26 – 100.83
- 52-week range
- 50.16 – 111.86
- Beta
- 0.03
- Price target
- 106.99 (+6.1%)
- Earnings date
- Nov 5, 2026
2Y -14.64 (-12.68%)
Key statistics
- Enterprise value
- 6.58B
- PEG ratio
- 0.00
- Price / sales
- 4.23
- Price / book
- 5.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2.70%
- Free cash flow
- 451.66M
- Total cash
- 593.30M
- Total debt
- 624.96M
- Return on equity
- 22.21%
- Short % of float
- 6.51%
- 50-day average
- 100.27
- 200-day average
- 91.56
Analyst view
- Target (low)
- 102.50
- Target (mean)
- 106.99
- Target (high)
- 115.00
- Strong buy1
- Buy1
- Hold8
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 1.26.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 1.24 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 1.30 | 1.55 | +0.25 | +19.23% |
| May 7, 2026 | Mar 31, 2026 | 1.25 | 1.46 | +0.21 | +16.80% |
| Feb 26, 2026 | Dec 31, 2025 | 1.18 | 1.67 | +0.49 | +41.53% |
| Nov 6, 2025 | Sep 30, 2025 | 1.27 | 1.27 | 0.00 | 0.00% |
| Aug 6, 2025 | Jun 30, 2025 | 1.64 | 1.57 | -0.07 | -4.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Mizuho | down | Outperform | Neutral |
| Aug 4, 2026 | Truist Securities | down | Buy | Hold |
| Aug 4, 2026 | CJS Securities | down | Market Outperform | Market Perform |
| Aug 3, 2026 | William Blair | down | Outperform | Market Perform |
| Aug 3, 2026 | TD Cowen | down | Buy | Hold |
| Jul 29, 2026 | Mizuho | main | Outperform | Outperform |
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- lantheus.com
News
Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting 
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday 
Mizuho Downgrades Lantheus Holdings to Neutral, Lowers Price Target to $109 
Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1 
Lantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401 
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics - Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease
- Lantheus Holdings Q2 Adj. EPS $1.55 Beats $1.30 Estimate, Sales $388.200M Beat $362.416M Estimate
- Truist Securities Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5
TD Cowen Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5
Your note
Sign in to keep a note on LNTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLANCHFIELD PAUL | President | Sale | Aug 12, 2025 | 108,214 |
| DINKELBORG LUDGER | Officer | Stock Award(Grant) | Mar 4, 2026 | 35,731 |
| FARALLON PARTNERS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 19, 2025 | 0 |
| HEINO MARY ANNE | Chief Executive Officer | Stock Award(Grant) | Mar 1, 2026 | 589,195 |
| LENO SAMUEL R | Director | Stock Award(Grant) | May 13, 2026 | 67,246 |
| MARKISON BRIAN A | Chief Executive Officer | Stock Award(Grant) | Mar 4, 2025 | 232,420 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.86% | 8,397,642 | 846.48M | Jun 29, 2026 |
| Farallon Capital Management LLC | 8.55% | 5,583,479 | 562.81M | Jun 29, 2026 |
| Jupiter Topco LLC | 7.95% | 5,188,416 | 522.99M | Jun 29, 2026 |
| FMR, LLC | 5.94% | 3,879,971 | 391.10M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.96% | 3,238,471 | 326.44M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.49% | 2,932,214 | 295.57M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.97% | 2,593,343 | 261.41M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 2,325,136 | 234.37M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 2,065,879 | 208.24M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.58% | 1,687,913 | 170.14M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 1,493,665 | 150.56M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 1.73% | 1,132,936 | 114.20M | Jun 29, 2026 |